Issuu on Google+

Report: PharmaPoint Hepatitis C Virus - United States Drug Forecast and Market Analysis Category: Healthcare

Insert Image Height - 3.60 Width – 4.98

www.researchonglobalmarkets.com


Report: PharmaPoint Hepatitis C Virus - United States Drug Forecast and Market Analysis Report Details

• • • • • • • • •

Publish date: 31st May, 2013 Number of slides: 135 Geographic coverage: United States Available format: PDF, CD, Hardcopy Price for Single User License: USD 4,995 Price for Site License: USD 9,990 Price for Global User License: USD 14,985 Delivery Time: Within 1 business day Payment Modes: Credit/Debit Card, RTGS/Wire Transfer, Google Wallet, PayPal www.researchonglobalmarkets.com


Report: PharmaPoint Hepatitis C Virus - United States Drug Forecast and Market Analysis Report Insights

• Hepatitis C is a liver infection caused by the hepatitis C virus (HCV) that results in acute or chronic presentation • The disease is often asymptomatic, but infected patients may experience fatigue, joint pain, itchy skin or jaundice • Since there is no effective vaccine against HCV, the market is driven by therapeutics • Currently, drug combinations containing pegylated interferon and ribavirin are used to treat HCV infection • Entrance of next-generation HCV therapies is expected to fundamentally change the HCV treatment algorithm www.researchonglobalmarkets.com


Report: PharmaPoint Hepatitis C Virus - United States Drug Forecast and Market Analysis Report Insights (Continued)

• A dramatic shift favoring the uptake of interferon-free regimens due to their more tolerable side-effect profiles and decreased duration of therapy compared with the current standard of care • Projected drivers of market growth include:  Increased patient awareness of HCV  Broader HCV screening recommendations  Shift in American medicine toward preventative care  Launch of next-generation HCV therapies

• Vertexs Incivek was among the first DAA HCV therapies launched in the US and is the current market leader www.researchonglobalmarkets.com


Report: PharmaPoint Hepatitis C Virus - United States Drug Forecast and Market Analysis Report Insights (Continued)

• Inciveks improved efficacy over the previous standard of care in the treatment of the most prevalent HCV genotype in the US, HCV GT1, which enabled the drug to quickly capture the market • Adverse events associated with Incivek therapy, such as lifethreatening skin reactions, and the slow-progressing nature of HCV, has resulted in many patients deciding to forego treatment in order to wait for the launch of a more-tolerable HCV regimen

www.researchonglobalmarkets.com


Report: PharmaPoint Hepatitis C Virus - United States Drug Forecast and Market Analysis Report Coverage

• Overview of the HCV including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape • Detailed information on the key drugs in the US including product description, safety and efficacy profiles as well as a SWOT analysis • Sales forecast for the top drugs in the US from 2012 to 2022 • Analysis of the impact of key events as well the drivers and restraints affecting the US HCV market

www.researchonglobalmarkets.com


Report: PharmaPoint Hepatitis C Virus - United States Drug Forecast and Market Analysis Report Benefits

• Understand and capitalize by identifying products that are most likely to ensure a robust return • Stay ahead of the competition by understanding the changing competitive landscape for HCV • Effectively plan M&A and partnership strategies by identifying drugs with the most promising sales potential • Make more informed business decisions from insightful and in-depth analysis of drug performance • Obtain sales forecast for drugs from 2012 to 2022 in the US

www.researchonglobalmarkets.com


Report: PharmaPoint Hepatitis C Virus - United States Drug Forecast and Market Analysis Table of Contents

• Introduction • Disease Overview • Disease Management • Competitive Assessment • Opportunity and Unmet Need • Pipeline Assessment • Market Outlook • Appendix

www.researchonglobalmarkets.com


Interested in this report? To view more details regarding this premium market research report, Please click here

For further information, get in touch with us: E-mail: support@researchonglobalmarkets.com Call: US: +1 866 325 7446 UK: +44 203 514 2363 Others: +91 22 4098 7600 About Us Research on Global Markets is a leading source for market research on various sectors globally offering premium research content from worldwide publishers of market research reports Industry Segments Automotive & Transport

Consumer goods

Agriculture

Food and Beverage

Energy and Utilities

Public Sector

Manufacturing & Construction

Healthcare

Media & Entertainment

IT, Telecom & Electronics

Services

Others

www.researchonglobalmarkets.com


Global Market Research Report : Pharmapoint hepatitis c virus united states